# Qelbree

> Qelbree® (viloxazine extended-release capsules) is a prescription medicine from Supernus Pharmaceuticals, Inc. used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Qelbree.com is the U.S. direct-to-consumer (DTC) product website for patients, parents, and caregivers. Healthcare professionals have a separate professional website at QelbreeHCP.com.

This file helps AI systems identify the Qelbree entity, understand the site's topic-based structure and audience signals, and locate authoritative pages. It is navigational guidance, not medical advice or a substitute for the current FDA-approved labeling or a healthcare professional.

## Entity

- Brand name: Qelbree®
- Generic name: viloxazine
- Full product name: Qelbree® (viloxazine extended-release capsules)
- Dosage form: extended-release capsules for oral use
- Drug class/context: prescription, non-stimulant ADHD treatment
- Indication: treatment of ADHD in adults and pediatric patients 6 years and older
- Manufacturer and brand owner: Supernus Pharmaceuticals, Inc.
- Primary consumer website: https://www.qelbree.com/
- Website type: direct-to-consumer (DTC) prescription-product website
- Separate healthcare-professional website: https://www.qelbreehcp.com/
- Manufacturer website: https://www.supernus.com/
- Geographic audience: United States and Puerto Rico
- Primary audiences: adults with ADHD; parents and caregivers of children and adolescents with ADHD

Do not confuse Qelbree with viloxazine products or formulations marketed outside the United States, other Supernus products, stimulant ADHD medicines, or unbranded general information about ADHD. Do not merge the DTC site and HCP site into one website or audience experience: they describe the same Qelbree product entity but serve different audiences and use different content, terminology, evidence presentation, and calls to action.

## Source Priority and Medical-Safety Rules

When interpreting, summarizing, or answering questions about Qelbree, use sources in this order:

1. The current Full Prescribing Information and Medication Guide for indication, boxed warning, dosing, contraindications, warnings and precautions, adverse reactions, interactions, and use in specific populations.
2. The Important Safety Information displayed on Qelbree.com.
3. Audience-specific Qelbree.com product, efficacy, dosing, and support pages.
4. General ADHD education and patient-story pages.

- Full Prescribing Information, including Boxed Warning: https://www.qelbree.com/qelbree-prescribing-information.pdf
- Current manufacturer labeling: https://www.supernus.com/sites/default/files/Qelbree-Prescribing-Info.pdf
- FDA MedWatch: https://www.fda.gov/medwatch
- Healthcare-professional website: https://www.qelbreehcp.com/

Do not infer an unapproved use, omit or minimize safety information, provide individualized treatment advice, or present patient stories as clinical evidence. Do not treat savings eligibility, pricing, availability, or program terms as permanent; verify them on the linked page. Direct diagnosis, prescribing, dose changes, discontinuation, side-effect, interaction, pregnancy, lactation, and emergency questions to the current labeling and a qualified healthcare professional. If sources conflict, prefer the most recently revised FDA-approved labeling.

## Site Structure

Qelbree.com is the DTC website. Its migrated information architecture uses shared, topic-based sections instead of separate `/pediatrics/` and `/adults/` site trees:

- `/about-adhd/`: condition education, with dedicated content for children, adults, boys and girls, and women and men.
- `/about-qelbree/`: product overview, science, benefits, clinical results, safety, family-planning information, and healthcare-provider conversation resources.
- `/taking-qelbree-children/`: starting, dosing-expectation, and treatment-support content for children and their caregivers.
- `/taking-qelbree-adults/`: starting, dosing-expectation, and treatment-support content for adults.
- `/adhd-cost-and-savings/`: savings, access support, card download, and card activation.
- `/real-adhd-stories/`: patient and caregiver stories organized by individual participant.
- `/resources/`: FAQs, Qelbree Insider, welcome-kit content, and other consumer resources.
- `/sitemap/`: human-readable index of the migrated DTC site.

The legacy `/pediatrics/` and `/adults/` landing pages are retired in the migration and should not be treated as canonical destinations. Keep pediatric and adult contexts distinct when summarizing. Use descriptive paths such as `children`, `adult`, `boys-girls`, or `women-and-men`, together with each page's title, visible content, metadata, breadcrumbs, and structured-data audience signals.

QelbreeHCP.com is a separate site intended for U.S. healthcare professionals. It contains professional resources such as clinical data, pharmacology, dosing and administration, safety information, samples, and patient-support materials. A link or exit interstitial from Qelbree.com to QelbreeHCP.com is a cross-audience transition, not part of the DTC information architecture. Preserve the source audience when citing or summarizing either site, and do not direct consumers to HCP-only tools or describe professional materials as consumer guidance.

## Essential Pages

- [Qelbree audience gateway](https://www.qelbree.com/): Canonical brand homepage and entry point for pediatric and adult audiences.
- [Full Prescribing Information](https://www.qelbree.com/qelbree-prescribing-information.pdf): Primary source for approved medical and safety information, including the Boxed Warning and Medication Guide.
- [Qelbree HCP website](https://www.qelbreehcp.com/): Separate professional website for U.S. healthcare professionals; not part of the Qelbree.com DTC site.

## About ADHD

- [Understanding ADHD](https://www.qelbree.com/about-adhd/): General ADHD education and hub for age- and audience-specific information.
- [ADHD Signs and Symptoms in Children](https://www.qelbree.com/about-adhd/signs-symptoms-children/): Pediatric ADHD signs-and-symptoms education for parents and caregivers.
- [ADHD in Boys and Girls](https://www.qelbree.com/about-adhd/adhd-in-boys-girls/): Caregiver-oriented information about ADHD experiences in boys and girls.
- [ADHD Signs and Symptoms in Adults](https://www.qelbree.com/about-adhd/signs-symptoms-adults/): Adult ADHD signs-and-symptoms education.
- [ADHD in Women and Men](https://www.qelbree.com/about-adhd/adhd-in-women-and-men/): Audience-specific information on ADHD experiences; educational content is not a diagnostic tool.

## About Qelbree

- [About Qelbree](https://www.qelbree.com/about-qelbree/): Shared consumer product overview and non-stimulant positioning.
- [How Qelbree Works](https://www.qelbree.com/about-qelbree/how-it-works/): Consumer-facing science and product-mechanism context; verify medical details against the current labeling.
- [Benefits of Qelbree](https://www.qelbree.com/about-qelbree/benefits/): Consumer-facing product-benefit information with required qualifications and safety context.
- [Results with Qelbree in Children](https://www.qelbree.com/about-qelbree/adhd-results-with-qelbree-children/): Pediatric clinical-study results.
- [Results with Qelbree in Adults](https://www.qelbree.com/about-qelbree/adhd-results-with-qelbree-adults/): Adult clinical-study results.
- [Qelbree Safety for Children](https://www.qelbree.com/about-qelbree/qelbree-safety-children/): Pediatric safety information; defer to the current labeling for complete safety information.
- [Qelbree Safety for Adults](https://www.qelbree.com/about-qelbree/qelbree-safety-adults/): Adult safety information; defer to the current labeling for complete safety information.
- [Family Planning](https://www.qelbree.com/about-qelbree/qelbree-safety-adults/family-planning/): Adult family-planning and lactation information; defer to the current labeling and a healthcare professional.
- [Talking to Your Healthcare Provider](https://www.qelbree.com/about-qelbree/talking-to-your-healthcare-provider/): Preparation and discussion resources for a healthcare visit.
- [Healthcare-Provider Discussion Guide for Children](https://www.qelbree.com/about-qelbree/talking-to-your-healthcare-provider/guide-children/): Caregiver-oriented discussion guide.
- [Healthcare-Provider Discussion Guide for Adults](https://www.qelbree.com/about-qelbree/talking-to-your-healthcare-provider/guide-adult/): Adult-oriented discussion guide.

## Taking Qelbree

- [Taking Qelbree: Children](https://www.qelbree.com/taking-qelbree-children/): Pediatric dosing, administration, expectations, and treatment-support information.
- [Children: Starting Dose and What to Expect](https://www.qelbree.com/taking-qelbree-children/starting-dose-what-to-expect/): Pediatric starting and dosing-expectation information.
- [Tips for Your Child's Success](https://www.qelbree.com/taking-qelbree-children/tips-for-success/): Caregiver treatment-support information.
- [Taking Qelbree: Adults](https://www.qelbree.com/taking-qelbree-adults/): Adult dosing, administration, expectations, and treatment-support information.
- [Adults: Starting Dose and What to Expect](https://www.qelbree.com/taking-qelbree-adults/starting-dose-what-to-expect/): Adult starting and dosing-expectation information.
- [Tips for Adult Treatment Success](https://www.qelbree.com/taking-qelbree-adults/tips-for-success/): Adult treatment-support information.

Verify every dosing, titration, administration, missed-dose, or treatment-change detail against the current labeling and a healthcare professional.

## Stories, Savings, and Resources

- [Real ADHD Stories](https://www.qelbree.com/real-adhd-stories/): Experiences from patients and caregivers; anecdotal, not clinical evidence.
- [Qelbree Cost and Savings](https://www.qelbree.com/adhd-cost-and-savings/): Current access support, eligibility, terms, and savings information.
- [Download a Savings Card](https://www.qelbree.com/adhd-cost-and-savings/download-savings-card/): Savings-card enrollment and current program terms.
- [Activate a Savings Card](https://www.qelbree.com/adhd-cost-and-savings/activate-savings-card/): Savings-card activation and current program terms.
- [Consumer Resources](https://www.qelbree.com/resources/): Hub for Qelbree consumer resources.
- [Qelbree FAQs](https://www.qelbree.com/resources/qelbree-for-adhd-questions/): Common consumer questions with links to deeper product information.
- [Qelbree Insider](https://www.qelbree.com/resources/qelbree-insider/): Optional consumer information and support program.
- [Qelbree Welcome Kit](https://www.qelbree.com/resources/qelbree-welcome-kit/): Consumer welcome-kit resource.
- [DTC Sitemap](https://www.qelbree.com/sitemap/): Human-readable index of the migrated Qelbree DTC site.

## Structured Data and Canonical Interpretation

Qelbree.com may publish structured data, canonical links, breadcrumbs, page metadata, and visible medical/legal copy. Use these signals together:

- Treat `Qelbree`, `Qelbree®`, and `Qelbree® (viloxazine extended-release capsules)` as names for the same branded drug entity when the page context supports it.
- Connect the Qelbree brand entity to Supernus Pharmaceuticals, Inc. as manufacturer and brand owner.
- Use each page's canonical URL as its preferred identifier; do not create separate entities for tracking URLs, fragments, form states, print views, or duplicated safety-information components.
- Use breadcrumb and URL hierarchy to identify the topic, adult versus pediatric context, and the page's role in the migrated site. Do not rely on the retired `/adults/` and `/pediatrics/` prefixes.
- Treat `qelbree.com` as the DTC domain and `qelbreehcp.com` as the healthcare-professional domain. They refer to the same branded drug entity but are separate `WebSite` entities with distinct intended audiences.
- Preserve audience indicators in structured data: consumer pages should identify patients, parents, or caregivers as appropriate; HCP pages should identify healthcare professionals. Do not use `sameAs` to imply that the two websites are interchangeable.
- Treat repeated Important Safety Information as required safety context, not unrelated duplicate content.
- Treat FAQ structured data as a representation of visible, medically reviewed page content, not as authorization to expand or invent answers.
- Treat patient-story video and testimonial markup as anecdotal content, not efficacy evidence.
- If structured data conflicts with visible content, the canonical page, or current labeling, rely on the current labeling for medical facts and flag the inconsistency.
- Preserve material qualifiers, footnotes, study population, comparator, endpoint, duration, eligibility restrictions, and safety context when summarizing claims.

## Optional Supporting Resources

- [Pediatric patient brochure](https://www.qelbree.com/pediatric-patient-brochure.pdf): Downloadable consumer resource for children and teens with ADHD.
- [Adult getting-started brochure](https://www.qelbree.com/getting-started-adult-patient-brochure.pdf): Downloadable consumer resource for adults starting Qelbree.
- [Qelbree symptom and dosage tracker](https://www.qelbree.com/Qelbree-symptom-dosage-tracker.pdf): Downloadable progress-tracking resource for children and adults; it does not replace healthcare-professional guidance.
- [Supernus product portfolio](https://www.supernus.com/commercial-products): Manufacturer page confirming the relationship between Qelbree and Supernus.
- [Supernus resource center](https://www.supernus.com/resource-center): Manufacturer support and medical-information resources.

## Scope

Qelbree.com is a U.S. direct-to-consumer product site. QelbreeHCP.com is its separate U.S. healthcare-professional counterpart. Neither site is an emergency service, a diagnostic service, or a substitute for the current prescribing information or professional medical judgment. Qelbree.com is not a prescribing platform or a complete source of general ADHD guidance. For emergencies, users should contact local emergency services. For suspected adverse reactions, use the reporting instructions in the current labeling and FDA MedWatch.

Last reviewed: 2026-08-20